ATE433493T1 - Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus - Google Patents

Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus

Info

Publication number
ATE433493T1
ATE433493T1 AT04798569T AT04798569T ATE433493T1 AT E433493 T1 ATE433493 T1 AT E433493T1 AT 04798569 T AT04798569 T AT 04798569T AT 04798569 T AT04798569 T AT 04798569T AT E433493 T1 ATE433493 T1 AT E433493T1
Authority
AT
Austria
Prior art keywords
herpes simplex
simplex virus
heterologue
nitroreductase
nucleic acid
Prior art date
Application number
AT04798569T
Other languages
English (en)
Inventor
Susanne Moira Brown
Paul Dunn
Original Assignee
Crusade Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crusade Lab Ltd filed Critical Crusade Lab Ltd
Application granted granted Critical
Publication of ATE433493T1 publication Critical patent/ATE433493T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04798569T 2003-11-17 2004-11-17 Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus ATE433493T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326798.6A GB0326798D0 (en) 2003-11-17 2003-11-17 Methods for generating mutant virus
PCT/GB2004/004851 WO2005049845A2 (en) 2003-11-17 2004-11-17 Oncolytic herpes simplex virus encoding a heterologous nitroreductase

Publications (1)

Publication Number Publication Date
ATE433493T1 true ATE433493T1 (de) 2009-06-15

Family

ID=29763982

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04798619T ATE484596T1 (de) 2003-11-17 2004-11-17 Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
AT04798569T ATE433493T1 (de) 2003-11-17 2004-11-17 Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04798619T ATE484596T1 (de) 2003-11-17 2004-11-17 Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom

Country Status (7)

Country Link
US (3) US20070110720A1 (de)
EP (3) EP1685254B1 (de)
JP (1) JP2007511215A (de)
AT (2) ATE484596T1 (de)
DE (2) DE602004029608D1 (de)
GB (1) GB0326798D0 (de)
WO (2) WO2005049845A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2007026146A1 (en) * 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0409596D0 (en) * 2004-04-29 2004-06-02 Crusade Lab Ltd Novel herpes simplex viruses and uses thereof
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
WO2010127361A1 (en) * 2009-05-01 2010-11-04 Vivebio, Llc Method of pooling and/or concentrating biological specimens for analysis
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
WO2012071276A1 (en) * 2010-11-23 2012-05-31 Xiaoliu Zhang Oncolytic virus as an inducer for innate antitumor immunity
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
EP2764119A2 (de) 2011-10-05 2014-08-13 Genelux Corporation Methoden zum nachweis der replikation oder kolonisierung eines biologischen therapiemittels
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
EP2662117A1 (de) 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus zur Behandlung von Leberkrebs
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
EP3491013A1 (de) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155-variante immunmodulatorische proteine und verwendungen davon
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3872180A1 (de) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Sekretierbare variante immunmodulatorische proteine und manipulierte zelltherapie
JP2020501589A (ja) 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド がんの治療
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CN110117577B (zh) * 2018-02-05 2023-10-24 中国科学院武汉物理与数学研究所 低毒单纯疱疹病毒系统及其构建方法和应用
WO2019213305A1 (en) * 2018-05-01 2019-11-07 Albert Einstein College Of Medicine HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USE
KR102662837B1 (ko) 2018-06-04 2024-05-03 카리디 바이오테라퓨틱스, 인크. 바이러스 치료법의 강화를 위한 세포-기반 비히클
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
EP3884041A2 (de) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Verfahren zur expansion des subsets von natürlichen killer (nk)-tellen und verwandte zusammensetzungen und verfahren
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
KR20230088306A (ko) 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5310671A (en) 1988-06-24 1994-05-10 British Technology Group Limited Fowlpox virus non-essential regions
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
EP1380651A2 (de) 1991-08-26 2004-01-14 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltendes rekombinantes Virus der Vogelpocken
JP4115514B2 (ja) * 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
EP0722493A1 (de) 1993-07-27 1996-07-24 THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY Veränderte dna-virusvektoren und ihre anwendungen
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
EP0753581A1 (de) 1995-07-10 1997-01-15 Immuno Ag Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe
ZA966287B (en) 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
CA2234877A1 (en) 1995-10-19 1997-04-24 St. Jude Children's Research Hospital Herpesvirus vectors and their uses
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6602499B1 (en) * 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
EP1153136A2 (de) * 1998-12-09 2001-11-14 The General Hospital Corporation Verbessertes verpacken von hsv-amplikons und herstellung von rekombinanten viralen vektoren
CA2383372C (en) * 1999-08-31 2010-04-13 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
EP1111061A1 (de) * 1999-12-20 2001-06-27 Universite Libre De Bruxelles Vektor mit doppelter Selektion
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
JP4810042B2 (ja) * 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
JP2004535813A (ja) * 2001-07-17 2004-12-02 ミルナー，アン，ジョセフィーヌ 遺伝子発現のサイレンシング
US20050013808A1 (en) 2001-08-21 2005-01-20 Grove Jane Isabel Nitroreductase enzymes
US7348418B2 (en) 2002-02-08 2008-03-25 Memorial Sloan-Kettering Cancer Center Carcinoma-related genes and polypeptides and methods of use thereof
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same

Also Published As

Publication number Publication date
WO2005049844A3 (en) 2005-10-20
WO2005049845A2 (en) 2005-06-02
US20070098689A1 (en) 2007-05-03
US20090208460A1 (en) 2009-08-20
EP2281897A3 (de) 2011-11-30
ATE484596T1 (de) 2010-10-15
US7498161B2 (en) 2009-03-03
DE602004029608D1 (de) 2010-11-25
WO2005049844A2 (en) 2005-06-02
EP1685254B1 (de) 2009-06-10
EP1692294A2 (de) 2006-08-23
GB0326798D0 (en) 2003-12-24
DE602004021496D1 (de) 2009-07-23
EP2281897A2 (de) 2011-02-09
US20070110720A1 (en) 2007-05-17
EP1685254A2 (de) 2006-08-02
JP2007511215A (ja) 2007-05-10
WO2005049845A9 (en) 2006-08-17
WO2005049845A3 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
DE602004021496D1 (de) Für eine heterologe nitroreduktase kodierender onkolytischer herpes simplex virus
WO2005049846A3 (en) Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
WO2004024872A3 (en) Method for expression of small antiviral rna molecules within a cell
ATE513910T1 (de) Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
ATE358732T1 (de) Anti-virale vektoren
Severson et al. cis-Acting signals in encapsidation of Hantaan virus S-segment viral genomic RNA by its N protein
PT95494A (pt) Processo para a producao de dna recombinante compreendendo sequencias derivadas de virus de rna, e manipulacoes geneticas que o utilizam
WO2006012221A3 (en) Target cell-specific short interfering rna and methods of use thereof
ATE519774T1 (de) Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
KR100469936B1 (ko) 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
WO2005054438A3 (en) Nucleic acid molecules containing recombination sites and methods of using the same
ES2073491T3 (es) Arn multifuncional con actividad de autoprocesamiento, su preparacion y su utilizacion.
Paolini et al. Enzymatic properties of hepatitis C virus NS3-associated helicase
MXPA02003422A (es) Alteracion de la expresion de genes con adnss producido in vivo.
DE69515652D1 (de) Verwendung von dna oligomeren zur hemmung von hiv durch reduktion ribosomaler leserasterverschichtung
ITRM20030335A1 (it) Sistema di espressione di sirna.
DK1383796T3 (da) Neurovirulent stamme af viruset West Nile og anvendelser heraf
MX2008002115A (es) Componentes de transporte de nitrato.
Hayes et al. Complete replication of a satellite RNA in vitro by a purified RNA-dependent RNA polymerase
Verma et al. Cryptic AUG is important for 48S ribosomal assembly during internal initiation of translation of coxsackievirus B3 RNA
ATE442441T1 (de) Virale expressionsvektoren für pflanzen
Moon Model-based design of synthetic antisense RNA for predictable gene repression
CN115896070B (zh) 一种新型基因组编辑工具EbCas12a-D141R及其在基因编辑中的应用
ATE509947T1 (de) Nukleinsäure involviert im responder phenotyp und deren verwendung
Chandrashekharan et al. Design of a novel regulatory circuit for expression of restriction endonucleases.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties